Cancer Immunotherapy for the Immunosuppressed: Dissecting the Conundrum of Safety and Efficacy-Reference-Cited by-同舟云学术

Cancer Immunotherapy for the Immunosuppressed: Dissecting the Conundrum of Safety and Efficacy

Published:2019-08-01 Issue:3 Volume:2 Page:53-54
ISSN:2666-2345
Container-title:Journal of Immunotherapy and Precision Oncology
language:en
Short-container-title:

Author:

Hajjar Joud¹

Affiliation:

1. Department of Pediatrics, Section of Immunology, Allergy, and Retrovirology, Baylor College of Medicine, The William T. Shearer Center for Human Immunobiology, Texas Children's Hospital, Houston, TX, USA

Publisher

Innovative Healthcare Institute

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://meridian.allenpress.com/innovationsjournals-JIPO/article-pdf/2/3/53/2874701/i2590-017x-2-3-53.pdf

Reference14 articles.

1. Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry;Mayor;J Allergy Clin Immunol,2018

2. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies;Fischer;J Allergy Clin Immunol,2017

3. Cancer burden in the HIV-infected population in the United States;Shiels;J Natl Cancer Inst,2011

4. Human immunodeficiency virus infection increases the risk of incident autoimmune hemolytic anemia: A population-based cohort study in Taiwan;Yen;J Infect Dis,2017

5. Cancer in the transplant recipient;Chapman;Cold Spring Harb Perspect Med,2013

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience;The Oncologist;2023-03-23

2. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and viral hepatitis: The MD Anderson Cancer Center experience;2022-08-11

3. Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response;Journal of Clinical Medicine;2022-06-11

4. Immunotherapy in Special and Rare Situations: A Brief Review;Journal of Immunotherapy and Precision Oncology;2021-07-22

5. Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question;Clinical and Translational Oncology;2021-02-13